IMR Press / EJGO / Volume 42 / Issue 5 / DOI: 10.31083/j.ejgo4205135
Open Access Original Research
Concurrent immunohistochemical testing of L1CAM and MMR proteins adds value in risk stratification of endometrial cancer: a proof of concept
Show Less
1 Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455, USA
2 Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Women’s Health, University of Minnesota, Minneapolis, MN 55455, USA
Eur. J. Gynaecol. Oncol. 2021 , 42(5), 887–892; https://doi.org/10.31083/j.ejgo4205135
Submitted: 15 July 2021 | Revised: 24 August 2021 | Accepted: 15 September 2021 | Published: 15 October 2021
(This article belongs to the Special Issue Endometrial Cancer)
Abstract

Objectives: Histologic classification along with clinical stage predominantly drive management of patients with endometrial cancer. However, current clinico-pathologic risk-based stratification has proven suboptimal, inciting efforts to identify additional molecular classifiers, such as L1CAM. This is of particular relevance for the TCGA-defined Nonspecific Molecular Profile (NSMP) and MMR-deficient (MMR-d) groups of tumors, both of which are classified as having an intermediate prognosis. In current practice, L1CAM immunostaining is reserved for NSMP tumors that have been classified as MMR-proficient. The aim of this study is to investigate L1CAM testing in tandem, rather than sequential with that of MMR. Methods: A total of 149 MMR-tested endometrial carcinoma cases from 2019–2020 were identified, of which, 45 had also undergone L1CAM immunostaining. Clinical information including grade, stage, and treatment was reviewed. This was correlated with percentage of L1CAM positivity and MMR-status. Results: L1CAM positivity was noted in 7/45 (15.6%) cases with 6/45 (13.3%) additional cases demonstrating only focal positivity. MMR deficiency was noted in 24/45 (53.3%) of the cases in which L1CAM was performed. Of the cases that showed L1CAM positivity, 6/7 (85.7%), were found to be MMR-deficient. Within the remaining group in which L1CAM was not performed, 24/104 (23.1%) of cases showed MMR deficiency. Conclusions: Current findings suggest that L1CAM positivity is not mutually exclusive when correlating with MMR status. Performing L1CAM immunostaining on all endometrial carcinomas may assist in appropriate treatment for patients with L1CAM positivity, and in particular, in MMR-proficient cases classified within the NSMP category.

Keywords
L1CAM
MMR
Endometrial cancer
Testing algorithm
Molecular classification
Figures
Fig. 1.
Share
Back to top